Investigational new drugs for the treatment of resistant pneumococcal infections

Antibiotic resistance in Streptococcus pneumoniae is not only increasing with penicillin but also with other antimicrobial classes including the macrolides, tetracyclines and sulfonamides. This trend with antibiotic resistance has highlighted the need for the further development of new anti-infectiv...

Full description

Saved in:
Bibliographic Details
Published inExpert opinion on investigational drugs Vol. 14; no. 8; p. 973
Main Authors Hoffman-Roberts, Holly L, C Babcock, Emily, Mitropoulos, Isaac F
Format Journal Article
LanguageEnglish
Published England 01.08.2005
Subjects
Animals
Anti-Bacterial Agents - chemistry
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Drug Resistance, Bacterial - drug effects
Drug Resistance, Bacterial - physiology
Drugs, Investigational - chemistry
Drugs, Investigational - pharmacology
Drugs, Investigational - therapeutic use
Humans
Microbial Sensitivity Tests - methods
Pneumococcal Infections - drug therapy
Pneumococcal Infections - microbiology
Online AccessGet more information

Cover

More Information
Summary:Antibiotic resistance in Streptococcus pneumoniae is not only increasing with penicillin but also with other antimicrobial classes including the macrolides, tetracyclines and sulfonamides. This trend with antibiotic resistance has highlighted the need for the further development of new anti-infectives for the treatment of pneumococcal infections, particularly against multi-drug resistant pneumococci. Several new drugs with anti-pneumococcal activity are at various stages of development and will be discussed in this review. Two new cephalosporins with activity against S. pneumoniae include ceftobiprole and RWJ-54428. Faropenem is in a new class of beta-lactam antibiotics called the penems. Structurally, the penems are a hybrid between the penicillins and cephalosporins. Sitafloxacin and garenoxacin are two new quinolones that are likely to have a role in treating pneumococcal infections. Oritavancin and dalbavancin are glycopeptides with activity against methicillin-resistant S. aureus and vancomycin-resistant Enterococcus spp. as well as multi-drug resistant pneumococci. Tigecycline is the first drug in a new class of anti-infectives called the glycycyclines that has activity against penicillin-resistant pneumococci.
ISSN:1744-7658
DOI:10.1517/13543784.14.8.973